The FDA informed Genzyme that it will re-inspect the company’s Allston Landing, MA manufacturing facility. The re-inspection is a follow-up to an inspection the agency conducted in May 2009 and is intended to verify that all CAPA identified in a February warning letter have been implemented. In a letter to Genzyme, the agency indicated that all promised actions had not been either fully or adequately implemented at the time of the May inspection.During the re-inspection, the FDA will also rev...